360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Gleevec

Image source: Freebase

Type: Product

Name: Gleevec

First reported 4 hours ago - Updated 3 hours ago - 1 reports

India’s Trade Practices 'Discriminatory and Unfair,' U.S. Businesses Charge

New coalition urges diplomatic action from Obama Administration to fight patent infringement, other trade violations.Jun. 18, 2013 Steve Minter | IndustryWeekComments 0What is in this article?:India’s Trade Practices 'Discriminatory and Unfair,' U.S. ... [Published Industry Week - 4 hours ago]

Entities: India, Mark Elliot, Discriminatory, United States

First reported 23 hours ago - Updated 23 hours ago - 1 reports

Actavis

Pay-for-delay deals can go on, Court rules, but not without legal risk

The Supreme Court split the baby on âpay-for-delayâ settlements, allowing them to continue but opening manufacturers that make them up to lawsuits.The Court ruled 5-3 to toss a Federal appeals court decision shielding such deals from legal reproach, but ... [Published Medical Marketing And Media - 23 hours ago]

Entities: Tim Anderson, Gleevec, Patent, Actavis, Novartis AG

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

U S Defense Threat Reduction Agency

Can Repurposed Cancer Drugs Counter Bioterror Threats?

Newswise - ST. LOUIS -- A Saint Louis University reer has received a contract worth up to $980,000 to see if two cancer medications have the potential of protecting U.S. troops from biological agents that could be unleashed during an attack.The U.S. Defense ... [Published Noodls - Jun 17 2013]

Entities: Tasigna, U S Defense Threat Reduction Agency, Gleevec, Virus

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Novartis AG

Novartis: 5 Year Revenue Outlook

Novartis (NVS) is a Swiss global pharmaceutical company with a $170 billion market cap and over $56 billion in combined sales in 2012. It has one of the most innovative drug pipelines among its pharmaceutical peers. However, Novartis has faced challenges ... [Published Seeking Alpha - Jun 13 2013]

Entities: Novartis AG, Drugs, Diovan, Tasigna

First reported Jun 12 2013 - Updated Jun 13 2013 - 5 reports

Gleevec

Novartis, Sun Pharma Gleevec patent battle moves to U.S.

After years of struggling for intellectual property rights over cancer drug Glivec in India, Novartis ($NVS) will now have to fight for patent protection in the U.S. as well. Rediff.com reports that Indian drugmaker Sun Pharma has sued the Swiss drug ... [Published FiercePharma - Jun 13 2013]

Entities: Gleevec, Sun Pharmaceutical Industries Ltd, Novartis AG, Patent

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

U.S. Groups Urge Congress to Probe India’s Trade Policies

Pharma, Trade Experts Urge Congress to Probe India’s Trade PoliciesChinese IP Protections for Pharma ImprovingCourt’s Rejection of Glivec Patent Could Dampen R&D Investments in India Expert: Glivec Patent Rejection Could Hurt R&D Investments in India ... [Published FDA News - Jun 13 2013]

Entities: India, Gleevec, Research & Development, Patent

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Sun Pharmaceutical Industries Ltd

Indian stocks to watch - June 13

GLOBAL MARKETS ROUNDUP* Nifty futures on the Singapore Exchange are 0.89 percent down and the MSCI-Asia Pacific index excluding Japan is down 1.8 percent.* Asian shares hovered near 2013 lows and Japanese stocks took another dive as the prospect of less ... [Published Reuters - Jun 13 2013]

Entities: Sun Pharmaceutical Industries Ltd, India, Assam Petrochemicals Ltd

First reported Jun 07 2013 - Updated Jun 08 2013 - 2 reports

Drug abuse

The question before the nation was clear. What takes precedence: access to medicines for all, or profits of multinationals?The final answer came from the Supreme Court in a case multinational drug maker Novartis had filed against Indian firm Natco. After ... [Published Financial Chronicle - Jun 08 2013]

Entities: Patent, India, Drugs

First reported Jun 05 2013 - Updated Jun 05 2013 - 2 reports

Targeted cancer therapy pioneers tapped to receive the 2013 $100,000 Taubman Prize

The Taubman Prize is presented annually by the Taubman Institute and is open to clinician-scientists â doctors with active patient practices who also conduct laboratory research â around the world.Â In keeping with the mission of the Taubman Institute, ... [Published Street Insider - Jun 05 2013]

Entities: Gleevec, imatinib, chronic myeloid leukemia, Cancer

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/hjlwz3/gleevec_chronic) has announced the addition of the "" report to their offering. GlobalData has released its new PharmaPoint Drug Evaluation report, . Chronic myeloid leukemia (CML) ... [Published Individual.com - Jun 05 2013]

Entities: chronic myeloid leukemia, Gleevec, market analysis, blast phase, Patient

First reported Jun 04 2013 - Updated Jun 04 2013 - 2 reports

Few Newer Drugs Work Better Than Old Standbys: Study

Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, drugmakers have barely improved on old standbys developed decades ago.New research shows that the effectiveness ... [Published NewsMax.com - Jun 04 2013]

Entities: Drugs, Placebo, Patient

First reported May 22 2013 - Updated May 23 2013 - 2 reports

Ariad's Cancer Drug Iclusig Extends The Gleevec Magic

Home » Blogs » Today, patients with CML (chronic myeloid leukemia) who take Novartis' (NVS) drug Gleevec and follow it up with the newer medications, are projected to survive an average of 30 years, says Dr Brian Druker, the genius inventor behind both ... [Published BioPortfolio - May 23 2013]

Entities: Gleevec, chronic myeloid leukemia, Brian Druker, Acute Lymphoblastic Leukemia

Quotes

If patients have "run out of all sorts of options, randomizing them to imatinib instead of placebo certainly slows down the rate of progression, even in the absence of a response, and certainly can [have an] impact on their overall quality of life and their natural history" he said

Imatinib rechallenge improves PFS in GIST, but not for long [Published Oncology Report - 7 hours ago]

"They soon realized that they can't make unique anti-viral medications and vaccines for every potential weapon of mass destruction, and now are developing broad-spectrum anti-infectives that would be effective against many pathogens" Buller said

Can Repurposed Cancer Drugs Counter Bioterror Threats? [Published Noodls - Jun 17 2013]

...notice from Sun, the Indian drugmaker filed for a declaratory judgment in the US court, urging it be allowed to market a generic version of Glivec. "Sun is entitled to a declaration that all claims of the '051 patent (related to Glivec) are not infringed and/or are invalid" Sun's plea filed on Friday said

Sun Pharma takes Novartis to US Court [Published Economic Times - Jun 13 2013]

...patent and will vigorously defend our intellectual property rights," Novartis New York media office said in response to a Business Standard query. "The complaint challenges the validity of the crystal form patent for Gleevec, which expires in 2019" Novartis said

Sun Pharma sues Novartis in US court [Published Sify - Jun 12 2013]

More Content

sort by: Date \| Relevance
India’s Trade Practices 'Discriminatory and Unf... [Published Industry Week - 4 hours ago]
Ariad's Iclusig in GIST Phase II Study [Published Yahoo! Finance - 5 hours ago]
Imatinib rechallenge improves PFS in GIST, but ... [Published Oncology Report - 7 hours ago]
Myriad Genetics, Inc. (MYGN): Big Pharma’s Inte... [Published InsiderMonkey.com - 9 hours ago]
Big Pharma's Intellectual Property Blues [Published Motley Fool - 12 hours ago]
Pay-for-delay deals can go on, Court rules, but... [Published Medical Marketing And Media - 23 hours ago]
Can Repurposed Cancer Drugs Counter Bioterror T... [Published Noodls - Jun 17 2013]
American Association for Cancer Research Congra... [Published American Association for Cancer Research - Jun 15 2013]
1 Thing You Always Wanted to Know About Drugs (... [Published Motley Fool Discussion Boards - Jun 14 2013]
Novartis: Financial Projection And Stock Valuation [Published Seeking Alpha - Jun 14 2013]
Pfizer’s India patents, revenue grow despite ad... [Published Livemint.com - Jun 13 2013]
Novartis, Sun Pharma Gleevec patent battle move... [Published FiercePharma - Jun 13 2013]
Novartis: 5 Year Revenue Outlook [Published Seeking Alpha - Jun 13 2013]
Sun Pharmaceutical Inds sues Novartis over canc... [Published Indian-Commodity - Jun 13 2013]
India's Sun To Sue Novartis To Allow Generic Be... [Published The Rose Sheet - Jun 13 2013]
U.S. Groups Urge Congress to Probe India’s Trad... [Published FDA News - Jun 13 2013]
Indian stocks to watch - June 13 [Published Reuters - Jun 13 2013]
Sun Pharma takes Novartis to US Court [Published Economic Times - Jun 13 2013]
Sun Pharma sues Novartis in US court [Published Sify - Jun 12 2013]
India needs to show the world it respects IP ri... [Published Financial Chronicle - Jun 10 2013]
'India needs to show the world it respects IP r... [Published Economic Times - Jun 10 2013]
How Big Pharma-designed cacophony against Ranba... [Published Firstpost.com - Jun 10 2013]
Now Available: Ambit Biosciences Corporation - ... [Published Live-PR.com - Jun 09 2013]
Companion Diagnostics Market, 2012-2023 [Published MarketResearch.com - Jun 08 2013]
Just Released: "PharmaPoint: Chronic Myeloid Le... [Published Live-PR.com - Jun 08 2013]
Drug abuse [Published Financial Chronicle - Jun 08 2013]
Drugs Less Effective Now Than 40 Years Ago [Published Inquisitr - Jun 07 2013]
The US has a love-hate relationship with the In... [Published Intellectual Asset Management - Jun 07 2013]
Google Penguin 2.0 Algorithm – What to do if yo... [Published MediaBUZZ - Jun 07 2013]
Performance Marketing Optimization Checklist [Published MediaBUZZ - Jun 07 2013]

Blogs

sort by: Date \| Relevance
The Myth of the New [Published PharmaGossip - Jun 04 2013] New Drugs Are Barely An Improvement Over Decades-Old Standbys, Study FindsBy Sharon BegleyNEW YORK, June 3 (Reuters) - Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, ...
Pending EC decision: Glivec, imatinib, Opinion ... [Published Pending EC decisions and European Public Assess ... - May 31 2013]
Huge Drug Cost Disparities Seen in Health Overhaul [Published Swampland - May 13 2013] (WASHINGTON) — Cancer patients could face high costs for medications under President Barack Obama‘s health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you’ll pay. To try to keep premiums low, some ...
Cancer Treatments ‘Unaffordable’ and Will Drive... [Published Pharma-Mag - May 09 2013] The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and healthcare systems that does not necessarily correlate with the survival benefit the drug provides, and which is driving the rapid transition to generics ...
OxyContin And The Art Of 'Evergreening' [Published PharmaGossip - May 01 2013] A few weeks back, we wrote about the Indian Supreme Court's rejection of Novartis's attempt to use "evergreening" to prolong its patent on Gleevec, sold as Glivec in India. That term refers to the trick of making small changes to a drug, usually one about ...

Audio/Video

sort by: Date \| Relevance
Google and Twitter’s April Fools’ Pranks, and More [Published WSJ.com Video - News - Apr 01 2013]
CRUK \| I'm alive because of research \| Paul [Published Cancer Research UK - YouTube Channel - Jan 07 2013]

Press Releases

sort by: Date \| Relevance
Targeted cancer therapy pioneers tapped to rece... [Published PR Newswire - Jun 05 2013]
Research and Markets: Gleevec (Chronic Myeloid ... [Published Business Wire Professional Services News - Jun 05 2013]
Japan Chronic Myeloid Leukemia Market Studied i... [Published Business Wire - May 23 2013]
LMC-Vivir con una enfermedad crónica [Published PR Newswire - Apr 05 2013]
The U.S.-India Business Council Expresses Uneas... [Published EON Manufacturing - Apr 02 2013]